E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
(Metastatic) Castration Resistant Prostate Cancer (mCRPC) |
(gemetastaseerd) castratieresistent prostaatkanker |
|
E.1.1.1 | Medical condition in easily understood language |
(metastatic) prostate cancer |
(uitgezaaide) prostaatkanker |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036909 |
E.1.2 | Term | Prostate cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10076506 |
E.1.2 | Term | Castration-resistant prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the decrease in the CNS side effect fatigue in frail mCRPC patients treated with a reduced dose of enzalutamide (120mg OD) compared to the standard dose of enzalutamide (160mg OD) after 6 weeks of treatment |
|
E.2.2 | Secondary objectives of the trial |
To determine the decrease in the CNS side effect fatigue in frail mCRPC patients treated with a reduced dose of enzalutamide (120mg OD) compared to the standard dose of enzalutamide (160mg OD) after 12 weeks, and 24 weeks of treatment
-To determine cognition impairment in frail mCRPC patients treated with a reduced dose of enzalutamide(120mg OD) compared to the standard dose of enzalutamide (160mg OD) after six weeks,12 weeks and 24 weeks of treatment
-To evaluate changes in depression score in frail mCRPC patients treated with a reduced dose of enzalutamide(120mg OD) compared to the standard dose of enzalutamide (160mg OD) after six weeks, 12 weeks and 24 weeks of treatment
-To correlate exposure (Ctrough) of enzalutamide and N-desmethylenzalutamide to the measured CNS side effects
-To determine the percentage(%) of subjects that remained on the allocated dose level until the end of the study
-To evaluate the effect of dose reduction on treatment efficacy according to PCWG3 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Frail male patients with PC who will start enzalutamide treatment within label
- Age at least 18 years
- Patient who are able and willing to give written informed consent prior to screening and enrolment
- Patients from whom it is possible to collect blood samples and who are willing to answer the questionnaires
- Life expectancy of > 6 months
- Capable of understanding and answering Dutch tests and questionnaires, as determined by the investigator
|
|
E.4 | Principal exclusion criteria |
-Other causes for cognition change:
- (change in dose of opioids/sedatives/benzodiazepines) during last 2 weeks before study)
-Use of psychostimulantia such as methylphenidate within 1 week of start of study
-Diagnosed with medical conditions that affect cognition: Dementia, Alzheimer disease, Parkinson’s disease, psychiatric disorders that affect cognition other than depression or anxiety complaints related to the disease
-Active infection or other comorbidities that may contribute to fatigue or cognition change within 4 weeks of study entry
-Clinical relevant anaemia
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary aim is to show that a reduced dose (120mg OD) results in less fatigue (measured by the change in FACIT-fatigue subscale score) after 6 weeks of therapy compared to the standard dose (160mg OD) for frail metastatic castration resistant prostate cancer patients. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
6 weeks from start of therapy |
|
E.5.2 | Secondary end point(s) |
-To explore if the change in FACIT-fatigue subscale score is different between the two arms of the study from start of therapy; an early measurement of fatigue is performed at 6 weeks, and to explore if there remains a difference between the two arms from baseline - up untill 6 months of therapy, the questionnaire is repeated after 6 months of therapy.
-To explore the change in FACIT-cognition subscale score over time: from baseline to 6 weeks, 12 weeks and 24 weeks after start of therapy between the two arms of the study (reduced dose vs standard dose)
-To explore the change in GDS-15 subscale score over time: from randomization to 6 weeks, 12 weeks and 24 weeks after start of therapy between the two arms of the study (reduced dose vs standard dose)
-To compare the percentage of patients that develop depression (score>5 ) on GDS-15 questionnaire between the two arms of the study (reduced dose vs standard dose) over time: after 6 weeks, 12 weeks and 24 weeks months after start if therapy
-To correlate the change in side effects with plasma concentrations (Ctrough) of enzalutamide and N-desmethyl enzalutamide
-To evaluate the proportion (%) of patients in control arm (standard dose) that remain on allocated dose level until the end of the study
-To evaluate treatment efficacy for both arms of the study according to PCWG3 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
6 weeks, 12 weeks and 24 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |